Compare CBIO & ENRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CBIO | ENRD |
|---|---|---|
| Founded | 2003 | N/A |
| Country | United States | Sweden |
| Employees | N/A | N/A |
| Industry | | EDP Services |
| Sector | | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 537.5M | 560.3M |
| IPO Year | 2013 | 2025 |
| Metric | CBIO | ENRD |
|---|---|---|
| Price | $13.97 | $4.15 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $26.67 | N/A |
| AVG Volume (30 Days) | ★ 376.0K | 153.2K |
| Earning Date | 04-29-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $18,500.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $279.20 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.72 | $3.40 |
| 52 Week High | $27.41 | $10.49 |
| Indicator | CBIO | ENRD |
|---|---|---|
| Relative Strength Index (RSI) | 31.82 | 43.91 |
| Support Level | $9.95 | $3.40 |
| Resistance Level | $18.53 | $7.72 |
| Average True Range (ATR) | 1.41 | 0.42 |
| MACD | -0.63 | 0.05 |
| Stochastic Oscillator | 7.61 | 58.68 |
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
Einride AB is a technology company that develops and operates digital, electric, and autonomous freight solutions. Its platform includes planning and optimization tools, autonomous technologies, electric heavy-duty vehicle fleets, and charging infrastructure. It serves customers across North America, Europe, and the Middle East. The company's solutions support customers in transitioning logistics operations to electric and autonomous systems. Its business model includes Freight-Capacity-as-a-Service (FCaaS) and Software-as-a-Service (SaaS) offerings delivered through an AI-based platform that manages aspects of electric and autonomous operations.